Disrupt Therapeutics
PrivateLast Round
Grant
Dec 19, 2025
Total Funding Raised
$538,000
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Disrupt Therapeutics is a biotechnology company that is developing DRT-101, a peptide-based drug for the treatment of cannabis use disorder (CUD).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Mental Health
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting, Government Contracts
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Disrupt Therapeutics Comparables
Compare Disrupt Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| PleoPharma, Inc. | 81% | |
| Aelis Farma SA | 75% | |
| Indivior Pharmaceuticals, Inc. | 73% |
Disrupt Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Dec 19, 2025 | ||||
| Grant | Oct 15, 2024 | ||||
| VC Round | Jan 1, 2024 | ||||
| Accelerator | Nov 1, 2023 | ||||
| Grant | Sep 28, 2023 | ||||
Seed | Jan 30, 2023 |
Disrupt Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Arquimedes Accelerator | Accelerator |
| Agencia Estatal de Investigación | Grant |
| Inveready | VC Round |
| Pompeu Fabra University | Seed |
| University of Barcelona | Seed |
| Center for Technological Development and Innovation | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 19, 2025
$380K grant received from Center for Technological Development and Innovation.
- Oct 15, 2024
$79K grant received from Agencia Estatal de Investigación
Disrupt Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Disrupt Therapeutics's valuation, stock price, and market status.
Is Disrupt Therapeutics a public or private company?
Disrupt Therapeutics is a private company.
What is the current stock price of Disrupt Therapeutics?
Disrupt Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is Disrupt Therapeutics worth (valuation)?
Valuation information for Disrupt Therapeutics is not publicly available.
Can I buy Disrupt Therapeutics stock?
Disrupt Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Disrupt Therapeutics's last funding round?
Disrupt Therapeutics's most recent funding round was Grant on December 19, 2025.
Who are the main investors in Disrupt Therapeutics?
Key investors in Disrupt Therapeutics include Arquimedes Accelerator, Inveready.
Will Disrupt Therapeutics IPO soon?
No public IPO plans have been announced for Disrupt Therapeutics.
How can I track Disrupt Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Disrupt Therapeutics's secondary market activity and sign up for updates.